• 7783 Citations
  • 33 h-Index
19982019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Hans Hammers is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Renal Cell Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Vascular Endothelial Growth Factor A Medicine & Life Sciences
Histone Deacetylase Inhibitors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma

Hahn, A. W., Drake, C., Denmeade, S. R., Zakharia, Y., Maughan, B. L., Kennedy, E., Link, C., Vahanian, N., Hammers, H. & Agarwal, N., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Open Access
Renal Cell Carcinoma
Immunotherapy
Kidney
Salvage Therapy
N-acetyllactosaminide alpha-1,3-galactosyltransferase
4 Citations (Scopus)

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Martínez Chanzá, N., Xie, W., Asim Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., Balakrishnan, A., Bowman, A., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, B., McKay, R. R., Tripathi, A., Pachynski, R., Hahn, A. W., Hsu, J. A., Shah, S. A., Lam, E. T. & 18 others, Rose, T. L., Mega, A. E., Vogelzang, N., Harrison, M. R., Mortazavi, A., Plimack, E. R., Vaishampayan, U., Hammers, H., George, S., Haas, N., Agarwal, N., Pal, S. K., Srinivas, S., Carneiro, B. A., Heng, D. Y. C., Bosse, D., Choueiri, T. K. & Harshman, L. C., Apr 1 2019, In : The Lancet Oncology. 20, 4, p. 581-590 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Cohort Studies
Retrospective Studies
Histology
Treatment Failure

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)

Amin, A., Plimack, E. R., Ernstoff, M. S., Lewis, L. D., Bauer, T. M., McDermott, D. F., Carducci, M., Kollmannsberger, C., Rini, B. I., Heng, D. Y. C., Knox, J., Voss, M. H., Spratlin, J., Berghorn, E., Yang, L. & Hammers, H., Mar 14 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 73.

Research output: Contribution to journalComment/debate

Open Access
Renal Cell Carcinoma
Immunotherapy
Safety
Neoplasms
Publications
Renal Cell Carcinoma
Human Body
Neoplasms
Therapeutics
Clone Cells
Kidney Neoplasms
Neoplasm Metastasis
Survival
Brain
Renal Cell Carcinoma